|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000205978 |
Summary for NYNRIN |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000205978 | Gene symbol | NYNRIN |
| Gene name | NYN domain and retroviral integrase containing | |
| HGNC | 20165 | |
| Entrez ID | 57523 | |
| Gene type | protein_coding | |
| Synonyms | NYNRIN|FLJ11811|CGIN1 | |
| UniProtAcc | Q9P2P1 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NYNRIN |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NYNRIN | 1.10e+03 | -1.32e+00 | 2.72e-01 | -4.87e+00 | 1.13e-06 | 3.99e-06 | KIRP |
| NYNRIN | 1.01e+03 | -2.00e+00 | 5.79e-01 | -3.45e+00 | 5.51e-04 | 2.00e-03 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NYNRIN | 1.73e+03 | -1.04e+00 | 2.15e-01 | -4.82e+00 | 1.41e-06 | 5.00e-06 | KIRC |
Top |
Sex-biased somatic mutation for NYNRIN |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NYNRIN |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg11152302 | chr14:24398266 | CGI:chr14:24398820-24399384 | promoter | 7.60e-01 | 8.64e-01 | -2.89e+00 | 3.86e-03 | 1.84e-02 | -1.05e-01 |
| ACC | cg12890903 | chr14:24398748 | CGI:chr14:24398820-24399384 | promoter | 4.97e-01 | 5.97e-01 | -2.29e+00 | 2.21e-02 | 3.69e-02 | -1.00e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg20911718 | chr14:24398285 | CGI:chr14:24398820-24399384 | promoter | 7.55e-01 | 6.21e-01 | 4.92e+00 | 8.80e-07 | 2.58e-05 | 1.34e-01 |
| LUSC | cg11152302 | chr14:24398266 | CGI:chr14:24398820-24399384 | promoter | 6.57e-01 | 4.90e-01 | 3.17e+00 | 1.50e-03 | 3.42e-03 | 1.67e-01 |
| LUSC | cg20911718 | chr14:24398285 | CGI:chr14:24398820-24399384 | promoter | 7.04e-01 | 5.36e-01 | 3.35e+00 | 8.11e-04 | 2.26e-03 | 1.68e-01 |
| COAD | cg11152302 | chr14:24398266 | CGI:chr14:24398820-24399384 | promoter | 6.60e-01 | 5.57e-01 | 2.69e+00 | 7.25e-03 | 1.11e-02 | 1.03e-01 |
| ESCA | cg01970716 | chr14:24397958 | CGI:chr14:24398820-24399384 | promoter | 5.87e-01 | 4.62e-01 | 2.14e+00 | 3.20e-02 | 4.44e-02 | 1.25e-01 |
| ESCA | cg08282145 | chr14:24399549 | CGI:chr14:24398820-24399384 | promoter,gene body | 3.32e-01 | 1.76e-01 | 2.62e+00 | 8.77e-03 | 3.58e-02 | 1.56e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg01970716 | chr14:24397958 | CGI:chr14:24398820-24399384 | promoter | 7.58e-01 | 6.43e-01 | 1.02e+01 | 2.65e-24 | 2.11e-23 | 1.14e-01 |
| BRCA | cg11152302 | chr14:24398266 | CGI:chr14:24398820-24399384 | promoter | 7.60e-01 | 4.78e-01 | 1.35e+01 | 2.15e-41 | 2.41e-39 | 2.81e-01 |
| BRCA | cg20911718 | chr14:24398285 | CGI:chr14:24398820-24399384 | promoter | 7.84e-01 | 5.35e-01 | 1.33e+01 | 2.66e-40 | 2.26e-38 | 2.49e-01 |
| BRCA | cg12890903 | chr14:24398748 | CGI:chr14:24398820-24399384 | promoter | 3.46e-01 | 1.71e-01 | 1.09e+01 | 1.22e-27 | 1.35e-26 | 1.75e-01 |
| BRCA | cg08282145 | chr14:24399549 | CGI:chr14:24398820-24399384 | promoter,gene body | 3.94e-01 | 1.70e-01 | 1.12e+01 | 5.09e-29 | 6.60e-28 | 2.23e-01 |
| KIRC | cg00822451 | chr14:24399379 | CGI:chr14:24398820-24399384 | promoter,exon,CDS,gene body | 1.77e-01 | 7.47e-02 | 3.30e+00 | 9.83e-04 | 4.47e-03 | 1.02e-01 |
| HNSC | cg08111832 | chr14:24398876 | CGI:chr14:24398820-24399384 | UTR,promoter,exon,gene body | 2.06e-01 | 9.03e-02 | 2.41e+00 | 1.60e-02 | 2.42e-02 | 1.16e-01 |
| COAD | cg01970716 | chr14:24397958 | CGI:chr14:24398820-24399384 | promoter | 3.68e-01 | 2.60e-01 | 2.90e+00 | 3.79e-03 | 7.77e-03 | 1.08e-01 |
Top |
Exon skipping events with PSI in TCGA for NYNRIN |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NYNRIN |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NYNRIN |
| TFs related to NYNRIN. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| NYNRIN related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NYNRIN |
| RBPs related to ES in NYNRIN. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| NYNRIN related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000205978 | LINC01224,hsa-mir-296,NYNRIN | Male-specific ceRNA | TCGA-KIRP |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7148652 | chr14:22730203:T:C | - | 0.248809399474743 | 0.00097852291031773 | GBM | Female-baised eQTL |
| rs1956468 | chr14:30222223:A:G | - | -0.193496814658248 | 0.0200461422681381 | GBM | Female-baised eQTL |
| rs1889770 | chr14:20867599:G:T | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs1957334 | chr14:20868013:G:C | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs10162412 | chr14:20868134:T:G | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs55686203 | chr14:20868135:G:A | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs10162377 | chr14:20868152:A:G | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs10162378 | chr14:20868224:A:G | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs11623018 | chr14:20868452:A:T | - | -0.193582313542016 | 0.0201232355590767 | GBM | Female-baised eQTL |
| rs73243906 | chr14:29891506:A:G | - | 0.178268447901526 | 0.0236082931286528 | GBM | Female-baised eQTL |
| rs72638499 | chr14:26035877:A:G | - | 0.176019480803327 | 0.0303580672430904 | GBM | Female-baised eQTL |
| rs35781229 | chr14:30254981:A:G | - | 0.180180808820541 | 0.0329581367726872 | GBM | Female-baised eQTL |
| rs11626639 | chr14:30211289:G:A | - | 0.183623461580351 | 0.0397256506554475 | GBM | Female-baised eQTL |
| rs2070335 | chr14:30222845:C:T | - | -0.175024861325031 | 0.0488299111170584 | GBM | Female-baised eQTL |
| rs12886256 | chr14:21697352:C:G | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs148483277 | chr14:21697987:C:T | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs77031885 | chr14:21706920:T:C | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs79400347 | chr14:21711472:C:T | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs80141418 | chr14:21712010:G:A | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs77716854 | chr14:21713038:C:T | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs80040208 | chr14:21713585:A:G | - | 0.224262920509823 | 0.000179741322198316 | KIRP | Female-baised eQTL |
| rs77120257 | chr14:21717471:T:C | - | 0.22398008478252 | 0.000193995095562733 | KIRP | Female-baised eQTL |
| rs74036966 | chr14:23262178:C:A | - | 0.144290289538471 | 0.0210628836078021 | KIRP | Female-baised eQTL |
| rs17111549 | chr14:26707064:A:G | - | 0.29879418429266 | 0.0381753050070946 | KIRP | Female-baised eQTL |
| rs73589794 | chr14:24801099:G:C | - | 0.137211654290209 | 0.0433459649671944 | KIRP | Female-baised eQTL |
| rs77031885 | chr14:21706920:T:C | - | 0.153660348947052 | 0.0172757575183243 | STAD | Female-baised eQTL |
| rs8015079 | chr14:29607881:G:T | - | 0.0961998857846663 | 0.0289786405860414 | STAD | Female-baised eQTL |
| rs61977964 | chr14:29612836:C:T | - | 0.0963541333769741 | 0.030172442761741 | STAD | Female-baised eQTL |
| rs8009861 | chr14:29616603:G:A | - | 0.0963541333769741 | 0.030172442761741 | STAD | Female-baised eQTL |
| rs146825904 | chr14:26107692:G:A | - | 0.109080986475106 | 0.0340208099051504 | STAD | Female-baised eQTL |
| rs45528634 | chr14:29627043:C:T | - | 0.0936081081421301 | 0.0420531960144679 | STAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs74242611 | chr14:21303708:C:T | - | 0.123977760912926 | 0.0176653871831193 | LIHC | Male-baised eQTL |
| rs17182473 | chr14:21302831:T:C | - | 0.123421886158932 | 0.0185340037925011 | LIHC | Male-baised eQTL |
| rs4981823 | chr14:20197728:G:C | - | -0.124968694972775 | 0.0213401470290985 | LIHC | Male-baised eQTL |
| rs77190401 | chr14:21309513:A:G | - | 0.117161552863091 | 0.0318406226159339 | LIHC | Male-baised eQTL |
| rs8005189 | chr14:26944474:A:G | - | -0.0595243968841151 | 0.0466277397950664 | KIRC | Male-baised eQTL |
| rs113730760 | chr14:26204396:C:T | - | 0.112213068524229 | 0.0180650903604614 | COAD | Male-baised eQTL |
| rs723880 | chr14:21923363:G:A | - | 0.0555307642252022 | 0.0231715316502033 | COAD | Male-baised eQTL |
| rs1546938 | chr14:26201816:T:C | - | 0.104349394052838 | 0.0274219715456959 | COAD | Male-baised eQTL |
| rs723878 | chr14:21923182:T:G | - | 0.0548109916584811 | 0.0275164904644695 | COAD | Male-baised eQTL |
| rs67902736 | chr14:21923183:T:A | - | 0.0548109916584811 | 0.0275164904644695 | COAD | Male-baised eQTL |
| rs10150821 | chr14:23424506:A:C | - | 0.0705943217533694 | 0.0313365890169959 | COAD | Male-baised eQTL |
| rs8008040 | chr14:21924631:T:C | - | 0.0534771914591973 | 0.0334013103521643 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000205978 |
| CpG Site: cg11152302 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.358270885652436 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg11152302 | chr14:24398266 | promoter | -0.358270885652436 | 9.62158373721025e-10 | -0.4360500205760737 | 2.933072816631375e-13 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NYNRIN |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
